News Conference News European Congress on Obesity 2025 App-Based Support Aids Weight Loss With Semaglutide, Studies Show Michael O'Riordan May 13, 2025
News Conference News Lifestyle Changes Can Curb CVD Risk After Adverse Pregnancy Outcomes Yael L. Maxwell March 26, 2024
News Conference News Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality Michael O'Riordan March 22, 2024
News Conference News ACC 2023 Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk Shelley Wood March 08, 2023
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News TCT 2021 EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI Michael O'Riordan October 15, 2021
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News EAS 2020 Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention Michael O'Riordan October 08, 2020
News Conference News ESC 2019 New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises Michael O'Riordan September 04, 2019
News Conference News ACC 2019 New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead Michael O'Riordan March 17, 2019
News Conference News ISC 2019 Should Pioglitazone Be Used More for Secondary Stroke Prevention in Prediabetes? Todd Neale February 14, 2019
News Conference News ESC 2018 Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND Michael O'Riordan August 26, 2018
News Conference News ESC 2018 Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61 Michael O'Riordan August 26, 2018
News Conference News AHA 2017 Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events Michael O'Riordan November 17, 2017